Quality Means Business (QMB), an emerging leader in AI-driven MedTech SaaS, has announced the raising of $2 million in seed funding to launch QualiVerse, a Regulatory Intelligence Engine that helps medical device innovators achieve compliance, accelerate product development, and scale safely to market. The funding round was led by The Boston Foundation’s Business Equity Investment Fund and CEI Ventures, both of which are focused on advancing technology that drives social and economic impact.
The investment positions QMB as a category-defining company at the intersection of AI, regulatory intelligence, and medical technology innovation. The funding will support QMB’s expansion of engineering efforts, enhancement of data integrations, and advancement of its RegTech-as-Infrastructure™ pilots with MedTech manufacturers expected to begin in late 2025.
QMB’s QualiVerse platform unifies design control, risk management, regulatory intelligence, and compliance scoring into a single enterprise system. It converts complex standards, such as ISO 13485, ISO 14971, IEC 62304, and EU MDR, into a workflow-aware operating system designed to accelerate product launches, reduce compliance risk, and deliver a measurable ROI across quality and regulatory teams.
The company’s governance team includes Michel Moravia, Chairman & CEO, who brings over 15 years of experience in MedTech regulatory and quality; Orlando Watkins, Board Director from The Boston Foundation; Robert Bennett, Board Director who scaled EngageSmart® to a private equity acquisition; and Shannon Bean, Board Observer from CEI Ventures.
Building on early enterprise traction and pilot interest from leading medical device companies, QMB is positioning QualiVerse as the intelligent infrastructure that turns compliance into a catalyst for innovation rather than an operational bottleneck.
KEY QUOTES:
“QMB is building the category infrastructure that MedTech has been missing. Michel’s vision is deeply informed by lived experience as both a regulator and SaaS product architect — and this is exactly the kind of entrepreneur we back to redefine industries.”
Anthony Rust, Fund Manager, Business Equity Investment Fund
“We’re excited to support QMB in bringing critical innovation to the MedTech sector. QualiVerse represents the type of transformative technology that not only drives business growth but also has the potential to improve patient outcomes on a global scale. This aligns perfectly with our mission to invest in companies that create meaningful economic opportunity while advancing social impact.”
Orlando Watkins, Vice President and Chief Program Officer, The Boston Foundation
“CEI Ventures is proud to partner with QMB. We’re especially proud that all current and planned jobs at QMB exceed the MIT Living Wage for Norfolk County, aligning with CEI Ventures’ Good Jobs Framework and our commitment to equitable, high-quality employment. QualiVerse is the rare platform that marries technical sophistication with impact at scale — accelerating safer devices to patients worldwide.”
Shannon Bean, Principal, CEI Ventures
“Quality and regulatory are the unsung heroes of medical innovation — they safeguard lives while too often operating in the shadows. With QualiVerse, we’re giving these teams the intelligent platform they deserve — a system that makes compliance not a bottleneck, but a catalyst for innovation. As both a MedTech regulatory veteran and product leader in enterprise SaaS, I know firsthand the cost of delay and the urgency of getting this right.”
Michel Moravia, Chairman & CEO, Quality Means Business
